Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy

Patients with chronic lymphocytic leukemia (CLL) who achieve blood or bone marrow (BM) undetectable minimal residual disease (U-MRD) status after first-line fludarabine, cyclophosphamide, and rituximab (FCR) have prolonged progression-free survival (PFS), when assessed by an assay with sensitivity 1...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2019-11, Vol.134 (22), p.1951-1959
Main Authors: Thompson, Philip A., Srivastava, Jaya, Peterson, Christine, Strati, Paolo, Jorgensen, Jeffrey L., Hether, Tyler, Keating, Michael J., O'Brien, Susan M., Ferrajoli, Alessandra, Burger, Jan A., Estrov, Zeev, Jain, Nitin, Wierda, William G.
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Cyclophosphamide - administration & dosage
Female
Flow Cytometry
Follow-Up Studies
High-Throughput Nucleotide Sequencing
Humans
Immunotherapy
Leukemia, Lymphocytic, Chronic, B-Cell - blood
Leukemia, Lymphocytic, Chronic, B-Cell - genetics
Leukemia, Lymphocytic, Chronic, B-Cell - mortality
Leukemia, Lymphocytic, Chronic, B-Cell - therapy
Lymphoid Neoplasia
Male
Middle Aged
Neoplasm, Residual
Predictive Value of Tests
Rituximab - administration & dosage
Vidarabine - administration & dosage
Vidarabine - analogs & derivatives
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with chronic lymphocytic leukemia (CLL) who achieve blood or bone marrow (BM) undetectable minimal residual disease (U-MRD) status after first-line fludarabine, cyclophosphamide, and rituximab (FCR) have prolonged progression-free survival (PFS), when assessed by an assay with sensitivity 10−4 (MRD4). Despite reaching U-MRD4, many patients, especially those with unmutated IGHV, subsequently relapse, suggesting residual disease
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.2019001077